CT109-ADC

CT109-ADC is a preclinical-stage antibody-drug conjugate (ADC) developed by Stromatis Pharma that targets both CEACAM5 and CEACAM6, two cell surface proteins frequently overexpressed in epithelial malignancies. The antibody component of the conjugate possesses dual specificity for these targets by binding to a shared glycoepitope centered on the N309 residue. CT109-ADC is designed to deliver potent cytotoxic payloads directly to tumor cells; variants have been developed using either the topoisomerase I inhibitor SN-38 or the microtubule-disrupting agent monomethyl auristatin F (MMAF). The lead candidate, CT109-SN-38, has shown significant antitumor activity in preclinical models of pancreatic cancer and other epithelial tumors, where CEACAM5/6 expression is associated with tumor progression, metastasis, and resistance to cell death.